Geron Announces Presentations on GRN163L and Its Telomerase Vaccine at the AACR Special Conference on the Role of Telomerase in Cancer
GRN163L Reduces Metastatic Potential of Tumor Cells
In the opening session of the meeting, Dr. Shay provided an overview of the importance of telomerase as a universal and highly specific target for the development of novel cancer therapies, and reviewed the breadth of approaches to kill telomerase-positive tumor cells while sparing normal tissue. Dr. Shay also presented new data from his laboratory indicating that Geron's novel oligonucleotide telomerase inhibitor, GRN163L, can have a relatively rapid effect on tumor cells in culture, making them less able to grow at low density (reduced clonogenicity), as well as inhibiting tumor cell invasion and migration through an extracellular matrix. These drug effects may be important to reduce the metastatic potential of cancer cells.
Full article: http://www.rednova.com/news/display/?id=101077
Posts
7 years ago
